Commercialising research

Our commercialisation team protects and exploits the University’s intellectual property, generated through its research, helping to maximise the economic, commercial and societal impact of that research.

The University places importance on supporting academics through the process of commercialising their research. This is evidenced through the University’s Enterprise Investment Fund (EIF), a significant annual fund which is dedicated to supporting commercialisation projects. Funding is available for staff to de-risk technologies developed at the University, ideally following validation via other internal Proof of Concept funds (e.g. UKRI Impact Acceleration Account (IAA) funding), and provide start-up investment to our spin-out companies.

Through our partnership with the NxNW consortium, our academics can access external accelerator programmes, such as the Innovate UK funded Innovation-to-Commercialisation of University Research (ICURe) Discovery and Explore schemes. 

Our technologies

View some of our latest research and technologies
Enterprise and Entrepreneurship

Enterprise and Entrepreneurship - a year of success

Read about our recent Research Commercialisation achievements and growing spin-out portfolio in our Enterprise and Entrepreneurship report.

Interview with Donna Bradshaw

Interview with Donna Bradshaw

Donna Bradshaw joined the University of Liverpool’s IP Commercialisation team as the first Entrepreneur Coach in Residence 2023.

Interview with Emma Nolan

An interview with Emma Nolan, Head of IP Commercialisation at the University of Liverpool.
Future Founders Programme

Future Founders Programme

Supporting early-stage academic founders who are ready to take on a director or ownership role of a developing business.

PhenUtest continues to go from strength-to-strength

The University of Liverpool spin-out company PhenUtest continues to build on their accomplishments

New University spin-out Sulantrix targeting untapped pseudoenzymes for new cancer medicines

A new University of Liverpool spin-out drug discovery company, Sulantrix, is exploring new medicines targeting cancer

New spin-out to deploy novel AI solution to reduce vision loss for people with diabetes

AI Sight will commercialise a next generation artificial intelligence (AI) system that will revolutionise diabetic eye screening

Tandem Nano and Medicines Patent Pool

Tandem Nano has signed a licence agreement with The Medicines Patent Pool (MPP) focused on the development of proprietary long-acting therapeutic technologies.

Meta Additive

University spin-out company, Meta Additive, acquired by Desktop Metal